Therapeutic approach to FSGS in children
Open Access
- 1 January 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in Pediatric Nephrology
- Vol. 22 (1), 28-36
- https://doi.org/10.1007/s00467-006-0310-4
Abstract
Therapy of primary focal segmental glomerulosclerosis (FSGS) in children incorporates conservative management and immunosuppression regimens to control proteinuria and preserve kidney function. In long-term cohort studies in adults and children with primary FSGS, renal survival has been directly associated with degree of proteinuria control. This educational article reviews the current therapeutic approach toward children with primary FSGS.This publication has 97 references indexed in Scilit:
- Differential risk of remission and ESRD in childhood FSGSPediatric Nephrology, 2006
- Recurrent focal glomerulosclerosis in pediatric renal allografts: the Miami experiencePediatric Nephrology, 2004
- Enalapril dosage in steroid-resistant nephrotic syndromePediatric Nephrology, 2004
- Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockadePediatric Nephrology, 2003
- Secondary resistance to cyclosporin A in children with nephrotic syndromePediatric Nephrology, 2002
- Peroxisome proliferator-activated receptor γ1 (PPARγ1) expresses in rat mesangial cells and PPARγ agonists modulate its differentiationBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2000
- Vitamin E treatment of focal segmental glomerulosclerosis: results of an open-label studyPediatric Nephrology, 1999
- Long-term therapy with enalapril in patients with nephrotic-range proteinuriaPediatric Nephrology, 1996
- Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosisPediatric Nephrology, 1996
- Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal diseaseThe Journal of Pediatrics, 1988